Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Xeraya Capital

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 25
Average round size
The average size of a deal this fund participated in
Portfolio companies 17
Rounds per year 2.50
Lead investments 7
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 5
Key employees 1

Areas of investment

  • Biotechnology
  • Health Care
  • Manufacturing
  • Medical Device
  • Therapeutics

The company was established in Asia in Malaysia. The main department of described VC is located in the Kuala Lumpur.

Considering the real fund results, this VC is 26 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2016. Despite it in 2019 the fund had an activity. Deals in the range of 10 - 50 millions dollars are the general things for fund. This Xeraya Capital works on 2 percentage points more the average amount of lead investments comparing to the other organizations. The fund is generally included in less than 2 deals every year. The top amount of exits for fund were in 2018.

For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight ViewRay, Acutus Medical, Rapid Micro Biosystems. Among the most popular fund investment industries, there are Health Diagnostics, Therapeutics. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups.

The overall number of key employees were 1.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Xeraya Capital, startups are often financed by OrbiMed, Khosla Ventures, Connecticut Innovations. The meaningful sponsors for the fund in investment in the same round are OrbiMed, OUP (Osage University Partners), Kearny Venture Partners. In the next rounds fund is usually obtained by OrbiMed, Kearny Venture Partners, Deerfield Capital Management.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Xeraya Capital:
Typical Co-investors
Xeraya Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Xeraya Capital:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Berggruen Holdings New York, New York, United States
Cascade Investment Fund -
Donghan International -
Good Capital New York, Tarrytown, United States
Haida Lianchuang Wuhan Touzi China, Hubei, Wuhan
Linden Asset Management Pennsylvania, Philadelphia, United States
Omaha Capital Nebraska, Omaha, United States
Plum Alley New York, New York, United States
Road Ventures Geneva, Geneve, Switzerland

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Greenlight Biosciences

$125M03 Feb 2022 Massachusetts, United States

OncoMyx Therapeutics

Health Diagnostics
$50M09 Dec 2021 Phoenix, Arizona, United States

OncoMyx Therapeutics

Health Care
$50M08 Dec 2021 Tempe, Arizona, United States

Imago BioSciences

Life Science
$80M19 Nov 2020 California, United States


Life Science
$34M16 Nov 2020 South San Francisco, California, United States


Health Care
$50M09 Nov 2020 Cambridge, England, United Kingdom

Rapid Micro Biosystems

$120M20 May 2020 Massachusetts, United States

Greenlight Biosciences

$17M12 May 2020 Massachusetts, United States

Aria CV

Health Care
Medical Device
$31M25 Feb 2020 Saint Paul, Minnesota, United States


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Xeraya Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: